Roche's Alecensa (alectinib) kept people with a specific lung cancer alive longer without their disease progressing than Pfizer's Xalkori (crizotinib), the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company's share of early treatment of the disease.
Alecensa, approved since 2015 in people with advanced ALK-positive non-small cell lung cancer who have failed on Xalkori, is now being trialed head-to-head against Pfizer's medication as an initial treatment.
"This is the second phase III trial to show that Alecensa was superior as an initial treatment compared to crizotinib in this type of lung cancer. The safety profile of Alecensa was consistent with that observed in previous studies, with no new or unexpected adverse events," the company said in a news release.
Roche said full data from the ALEX study will be presented at an upcoming medical meeting and submitted to global health authorities, including the U.S. Food and Drug Administration (FDA), which in September 2016 granted Alecensa breakthrough therapy designation for the treatment of people with advanced ALK-positive NSCLC who have not received prior treatment with an ALK inhibitor.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου